Evidence map›Paper›PMID 30880944›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

COPD patients' characteristics, usual care, and adherence to guidelines: the Greek UNLOCK study.

Ioanna Tsiligianni, Maria Kampouraki, Despo Ierodiakonou, Ioannis Poulonirakis, Polyvios Papadokostakis

Abstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain.International journal of chronic obstructive pulmonary disease
    Article
  17. Towards Rational Prescription of Common Inhaler Medication in the Multimorbid COPD Patient.International journal of chronic obstructive pulmonary disease
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ioanna TsiligianniDepartment of Social Medicine, Faculty of Medicine, University of Crete, Herkalion, Crete, Greece, i.tsiligianni@uoc.gr.
Maria KampourakiPrimary Care Practice, Health Center of Moires, Heraklion, Crete, Greece.
Despo IerodiakonouHeraklion University Hospital, Heraklion, Crete, Greece.
Ioannis PoulonirakisPrimary Care Practice, Health Center of Agia Varvara, Heraklion, Crete, Greece.
Polyvios PapadokostakisPrimary Care Practice, Garipa, Herkalion, Crete, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGOLD guidelines classify COPD patients into A-D groups based on health status as assessed by COPD Assessment Test (CAT) or mMRC tools and exacerbations and recommend single or dual long-acting bronchodilators as maintenance therapy, with additional inhaled corticosteroids (ICS) if the disease remains uncontrolled. We aimed to classify primary care COPD patients into A-D groups, assess usual treatment and adherence to guidelines, potential mismatches between CAT-and mMRC-based classification and described symptoms within groups. PATIENTS AND

methodsA total of 257 primary care COPD patients were enrolled between 2015 and 2016 in Greece. Physicians used structured interviews to collect cross-sectional data including demographics, symptoms, CAT, mMRC scores, and medications. Patients were classified into A-D groups based on CAT and mMRC, and prevalence of symptoms and medication was estimated within A-D groups. Interviews with physicians were also performed to explore additional issues about treatment and adherence to guidelines.

resultsMean (SD) age was 65 (12.3) years with 79% males. The majority of patients reported uncontrolled symptoms (91% and 61% with ≥10 CAT or ≥2 mMRC scores, respectively). Thirty-seven percentage had $2 exacerbations in the past year. Group B was the largest followed by Groups D, A, and C. Patients were classified as more severe by CAT than by mMRC. In all groups, the majority were treated with combined long-acting beta agonist/ICS (> 50%). When patients were asked to report their main symptoms, dyspnea and cough were the most important symptoms mentioned, and there was a great variation between the A-D groups. However, Groups A-C reported mainly morning symptoms, whereas Group D suffered symptoms all day. Physicians reported a significant number of barriers to implementing guidelines, eg, frequent lack of guideline updates, access to diagnostic procedures, and prescription-reimbursement issues.

conclusionOur study confirms poor adherence to guidelines regarding treatment with an overuse of ICS and important barriers to implementation. A mismatch in classification occurs depending on the tool used, which can mislead clinicians in their choice of treatment.

Indexed as

Practice Guidelines as TopicAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsAgedBronchodilator AgentsCross-Sectional StudiesDisease ProgressionDrug CombinationsFemaleGreeceGuideline AdherenceHealth Care SurveysHealth StatusHumansLungMaleAdrenal Cortex HormonesAdrenergic beta-2 Receptor AgonistsBronchodilator AgentsDrug CombinationsMuscarinic AntagonistsadherenceCATclassificationCOPDGOLD guidelinesmMRCsymptomsusual care

Identifiers

PMID30880944
PMCPMC6402614

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.